

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

白川, 剛

<https://hdl.handle.net/2324/7182254>

出版情報 : Kyushu University, 2023, 博士 (医学), 論文博士
バージョン :
権利関係 : Creative Commons Attribution 4.0 International





OPEN

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Tsuyoshi Shirakawa^{1,2}, Akitaka Makiyama^{3,4}, Mototsugu Shimokawa^{5,6}, Taiga Otsuka^{7,8}, Yudai Shinohara³, Futa Koga⁹, Yujiro Ueda¹⁰, Junichi Nakazawa¹¹, Satoshi Otsu¹², Azusa Komori^{12,13}, Shiho Arima¹⁴, Masaru Fukahori^{15,16}, Hiroki Taguchi^{17,18}, Takuya Honda¹⁹, Taro Shibuki^{20,21}, Kenta Nio^{22,23}, Yasushi Ide^{24,25}, Norio Ureshino^{26,7}, Toshihiko Mizuta^{20,27}, Kenji Mitsugi^{22,23}✉, Koichi Akashi²⁸ & Eishi Baba²⁹

There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated relationships between overall survival (OS) and six inflammatory markers; C-reactive protein/albumin ratio (CAR), neutrophil–lymphocyte ratio (NLR), prognostic nutrition index (PNI), platelet–lymphocyte ratio (PLR), Glasgow prognostic score (GPS), and prognostic index (PI). We examined 255 patients who received gemcitabine + nab-paclitaxel or FOLFIRINOX as first-line chemotherapy and 159 patients who subsequently underwent second-line chemotherapy. First-line patients with lower CAR had better OS compared to those with a higher CAR (hazard ratio 0.57; 95% confidential index 0.42–77; $P < 0.01$). Similarly, lower NLR ($P = 0.01$), higher PNI ($P = 0.04$), lower PLR ($P = 0.03$), GPS score of 0 ($P < 0.01$) and PI score of 0 ($P < 0.01$) were all associated with better OS. CAR demonstrated the best superiority for determining survival prognosis through the use of area under the curve of time-dependent receiver-operating characteristic curves. Furthermore, a lower CAR before second-line therapy exhibited better OS versus higher CAR ($P < 0.01$). Therefore, CAR might be a useful biomarker for predicting urPC patient prognosis in both first- and second-line chemotherapy.

¹Department of Medical Oncology, Fukuoka Wajiro Hospital, 2-2-75 Wajirogaoka, Higashi-Ku, Fukuoka-Shi, Fukuoka 811-0213, Japan. ²Department of Internal Medicine, Karatsu Higashi-Matsuura Medical Association Center, 2566-11 Chiyoda-machi, Karatsu-Shi, Saga 847-0041, Japan. ³Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-Ku, Kitakyushu-Shi, Fukuoka 806-8501, Japan. ⁴Cancer Center, Gifu University Hospital, 1-1 Yanagido, Gifu-Shi, Gifu 501-1194, Japan. ⁵Clinical Research Institute, National Kyushu Cancer Center, 3-1-1 Notame, Minami-Ku, Fukuoka-Shi, Fukuoka 811-1395, Japan. ⁶Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube-Shi, Yamaguchi 755-8505, Japan. ⁷Department of Medical Oncology, Saga-Ken Medical Center Koseikan, 400 Kase-Machi, Saga-Shi, Saga 840-8571, Japan. ⁸Department of Internal Medicine, Minato Medical Clinic, 3-11-3 Nagahama, Chuo-Ku, Fukuoka-Shi, Fukuoka 810-0072, Japan. ⁹Department of Hepatobiliary and Pancreatology, Saga-Ken Medical Center Koseikan, 400 Kase-Machi, Saga-Shi, Saga 840-8571, Japan. ¹⁰Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, 2-1-1 Nagamine-Minami, Higashi-Ku, Kumamoto-Shi, Kumamoto 861-8520, Japan. ¹¹Department of Medical Oncology, Kagoshima City Hospital, 37-1 Uebara-Cho, Kagoshima-Shi, Kagoshima 890-8760, Japan. ¹²Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-Machi, Yufu-Shi, Oita 879-5593, Japan. ¹³Department of Gastrointestinal Medical Oncology, National Hospital Organization

Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama-Shi, Ehime 791-0280, Japan. ¹⁴Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima-Shi, Kagoshima 890-8520, Japan. ¹⁵Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume-Shi, Fukuoka 830-0011, Japan. ¹⁶Kyoto Innovation Center for Next Generation Clinical Trials and iPSC Cell Therapy (Ki-CONNECT), Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-Ku, Kyoto 606-8507, Japan. ¹⁷Department of Gastroenterology, Saiseikai Sendai Hospital, 2-46 Harada-Cho, Satsumasendai-Shi, Kagoshima 895-0074, Japan. ¹⁸Department of Gastroenterology, Kagoshima City Hospital, 37-1 Uearata-Cho, Kagoshima-Shi, Kagoshima 890-8760, Japan. ¹⁹Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki-Shi, Nagasaki 852-8501, Japan. ²⁰Department of Internal Medicine, Imari Arita Kyoritsu Hospital, 860 Ninose-Ko, Arita-Cho, Nishi-Matsuura-Gun, Saga 849-4193, Japan. ²¹Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanohara, Kashiwa-Shi, Chiba 277-8577, Japan. ²²Department of Medical Oncology, Sasebo Kyosai Hospital, 10-17 Shimanji-Cho, Sasebo-Shi, Nagasaki 857-8575, Japan. ²³Department of Medical Oncology, Hamanomachi Hospital, 3-3-1 Nagahama, Chuo-Ku, Fukuoka-Shi, Fukuoka 810-8539, Japan. ²⁴Department of Internal Medicine, Karatsu Red Cross Hospital, 2430 Watada, Karatsu-Shi, Saga 847-8588, Japan. ²⁵Department of Internal Medicine, National Hospital Organization Saga Hospital, 1-20-1 Hinode, Saga-Shi, Saga 849-8577, Japan. ²⁶Department of Medical Oncology, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu-Shi, Chiba 292-8535, Japan. ²⁷Department of Internal Medicine, Fujikawa Hospital, 1-2-6 Matsubara, Saga-Shi, Saga 840-0831, Japan. ²⁸Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ²⁹Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ✉email: kenji.mitsugi@sb.kkr.or.jp

Pancreatic cancer remains one of the cancers with the poorest survival rates. It is the fourth leading cause of cancer-related death in Japan, and the seventh leading cause of cancer-related death worldwide^{1,2}. While surgical resection can be a curative treatment for localized pancreatic cancer, just 15% of pancreatic cancer patients are viewed as being candidates for curative resection, as approximately 80% of these patients have unresectable cancers at the time of diagnosis³.

Palliative chemotherapy is indicated for unresectable pancreatic cancer patients, with a large increase in recent years in the development of new treatments. Based on the results of prospective randomized phase 3 trials, gemcitabine + nab-paclitaxel (GnP) or FOLFIRINOX (FFX) have now become the standard first-line chemotherapy treatments for metastatic pancreatic cancer^{4,5}. The median overall survival (OS) for the GnP and FFX cases has been reported to be 8.5 months and 11.1 months, respectively^{4,5}. Second- or later-line chemotherapy, such as nanoliposomal irinotecan with fluorouracil and folic acid, fluorouracil-based, and gemcitabine-based regimens have been shown to have efficacy for pancreatic cancer, with a median OS of 3 to 9 months^{6–9}. Moreover, olaparib exhibited an anticancer effect after use as first-line chemotherapy for BRCA-mutated cases¹⁰. However, the overall prognosis for pancreatic cancer remains poor, with the 5-year survival being less than 10%^{11,12}.


Although there should be some reasons as to why pancreatic cancer has such a poor prognosis, at the current time we only have limited absolute biomarkers that can be used to evaluate the prognosis or determine the risk stratification prior to the implementation of the first-line chemotherapy^{13,14}. Furthermore, it remains unknown as to what types of patients second-line chemotherapy could potentially bring survival benefits to. As many patients who are at an unresectable stage receive palliative chemotherapy, it is very important to be able to identify both reliable and easily obtainable markers that can be used for better risk stratification of survival and optimal treatment plans. For example, if the prognosis of pancreatic cancer patients could be evaluated more accurately, this would make it possible to assess indications for chemotherapy or choice of regimen, thereby potentially providing more personalized therapy.

Inflammatory markers have possibility for use as prognostic biomarkers. It has been previously reported that there is a correlation between inflammation and malignant tumors¹⁵. Furthermore, other studies have shown that pretreatment serum inflammatory markers, such as C-reactive protein (CRP), the CRP/albumin ratio (CAR), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the modified Glasgow prognostic score (mGPS), are related to the prognosis for various types of cancer^{16,17}. However, the prognostic value of these markers has yet to be fully examined, especially in patients with unresectable pancreatic cancer who are classified as candidates for first- and second-line palliative chemotherapy. Therefore, the present study focused on comparing and examining the prognostic significance of different inflammatory markers in patients with unresectable pancreatic cancer who are seen during routine clinical practice.

Results

Patient characteristics. From December 2013 to March 2017, FFX and GnP were initially administered to 118 and 200 patients with unresectable pancreatic cancer, respectively. After excluding 63 locally advanced cases, 102 and 153 patients being administered FFX or GnP, respectively, were analyzed in Cohort 1 (Fig. 1). In this group, there were 96 cases that were excluded, with 77 receiving best supportive care, 10 continuing first-line chemotherapy, 5 undergoing surgery¹⁸ and 4 being lost to follow-up. In Cohort 2, there were 14, 62, and 83 patients who were subsequently treated with the FFX, GnP, or others, respectively.

Table 1 summarizes the baseline characteristics, and Table 2 summarizes the baseline laboratory data. By the end of the follow-up period on July 31, 2018, a total of 197 patients (61.9%) had died. Of these, 195 died from pancreatic cancer, while 2 died from other diseases. The median OS was 11.5 months for the FFX group and 11.1 months for the GnP group¹⁹. The median follow-up duration was 10.7 months (95% confidential index (95%CI), 9.8–11.5).



*Others (n): gemcitabine plus S-1 (11), gemcitabine plus erlotinib (1), fluorouracil/1-leucovorin plus oxaliplatin (1), gemcitabine (16), S-1 (51), S-1 plus radiation (1), everolimus (1) and hepatic arterial infusion chemotherapy (1)

Figure 1. Flow diagram of criteria for patient inclusion or exclusion. *FFX* FOLFIRINOX, *GnP* gemcitabine plus nab-paclitaxel.

Characteristics		Cohort 1 (n = 255)	Cohort 2 (n = 159)
Age, years	Median (range)	65 (29–86)	64 (29–87)
Sex, n (%)	Male	158 (62)	92 (58)
ECOG PS, n (%)	0	161 (63)	63 (40)
	1	78 (31)	74 (47)
	≥ 2	16 (6)	21 (13)
	Unknown	–	1 (1)
Malignant history, n (%)	Yes	34 (13)	19 (12)
Malignant family history, n (%)	Yes	75 (29)	48 (30)
Previous tumor resection, n (%)	Yes	44 (17)	20 (13)
Previous biliary drainage, n (%)	Yes	65 (26)	39 (25)
Pancreatic tumor location, n (%)	Head	123 (48)	75 (47)
	Body/tail	132 (52)	84 (53)
Histology, n (%)	Adenocarcinoma	212 (83)	138 (87)
	Others	10 (4)	3 (2)
	Unknown	33 (13)	18 (11)
Site of metastatic disease, n (%)	Liver	154 (60)	100 (63)
	Peritoneum	62 (24)	37 (23)
	Lung	39 (15)	22 (14)
Number of metastatic sites, n (%)	≥ 2	97 (38)	59 (37)
Ascites, n (%)	Yes	56 (22)	29 (18)
First-line chemotherapy, n (%)	FFX	102 (40)	80 (50)
	GnP	153 (60)	79 (50)

Table 1. Baseline characteristics. *ECOG PS* Eastern Cooperative Oncology Group performance status, *FFX* FOLFIRINOX, *GnP* gemcitabine plus nab-paclitaxel.

Inflammatory markers in first-line chemotherapy. Subsequently, we then analyzed the OS of patients after dividing them into two groups based on their respective inflammatory marker values. The median OS of the CAR < 0.54 group was 12.1 months, while it was 7.2 months in the CAR ≥ 0.54 group. There was a statistically significant difference between the groups (hazard ratio (HR) for death, 1.92; 95%CI, 1.40–2.64; $P < 0.01$; Fig. 2a). The median OS of the NLR < 5 group was 11.7 months, while it was 8.1 months in the NLR ≥ 5 group, a difference that was statistically significant (HR for death, 1.72; 95%CI, 1.20–2.45; $P < 0.01$; Fig. 2b). Similarly, the median OS was 11.5 months for the prognostic nutrition index (PNI) ≥ 47 group, while it was 11.3 months for the PNI < 47 group (HR 1.22; 95%CI 0.91–1.63; $P = 0.19$; Fig. 2c). The median OS was 12.5 months for the

Characteristics		Cohort 1 (n = 255)	Cohort 2 (n = 159)
White blood cell count, / μ L	Median (range)	6050 (2400–23,650)	4750 (1620–21,910)
Neutrophil count, / μ L	Median (range)	3940 (770–20,810)	2900 (610–21,250)
Lymphocyte count, / μ L	Median (range)	1360 (230–8640)	1080 (190–3030)
Platelet count, $\times 10^4$ / μ L	Median (range)	20.7 (6.7–56.1)	18.3 (2.4–79.8)
Albumin concentration, g/dL	Median (range)	3.8 (2.2–4.8)	3.6 (1.5–4.6)
CRP, mg/dL	Median (range)	0.33 (0.01–17.00)	0.58 (0.01–16.33)
LDH, U/L	Median (range)	180 (74–1320)	208 (84–713)
CEA, ng/mL	Median (range)	5.5 (0.4–626.6)	7.5 (1.0–1379.3)
CA19-9, U/mL	Median (range)	832 (1–6,554,100)	1254 (1–7,200,000)
NLR	Median (range)	3.02 (0.28–36.88)	2.68 (0.37–49.4)
	≥ 5.00 , n (%)	46 (18)	34 (21)
PLR	Median (range)	150.9 (16.1–1344.8)	164.5 (35.8–1270.0)
	≥ 150.0 , n (%)	128 (50)	89 (56)
PNI	Median (range)	45 (25–66)	42 (19–54)
	< 47 , n (%)	157 (62)	133 (84)
CAR	Median (range)	0.084 (0.002–7.182)	0.157 (0.003–6.387)
	≥ 0.540 , n (%)	62 (24)	40 (25)
GPS, n (%)	0	146 (57)	80 (50)
	1	62 (24)	48 (30)
	2	47 (18)	31 (20)
PI, n (%)	0	165 (65)	100 (63)
	1	82 (32)	49 (31)
	2	8 (3)	10 (6)

Table 2. Baseline laboratory data. *CRP* C-reactive protein, *LDH* lactate dehydrogenase, *CEA* carcinoembryonic antigen, *CA19-9* carbohydrate antigen 19–9, *NLR* neutrophil-to-lymphocyte ratio, *PLR* platelet-lymphocyte ratio, *PNI* prognostic nutrition index, *CAR* CRP-albumin ratio, *GPS* Glasgow prognostic score, *PI* prognostic index.

PLR < 150 group, while it was 10.1 months for the PLR ≥ 150 group (HR 1.34; 95%CI 1.01–1.78; $P = 0.04$; Fig. 2d). In addition, patients with a GPS score of 1 (median OS, 10.1 months) had a significantly better OS as compared to those with a GPS score of 2 (median OS, 6.7 months), respectively (score of 1 HR, 1.56; 95%CI, 1.11–2.20; $P = 0.01$; score of 2 HR, 2.05; 95%CI, 1.43–2.93; $P < 0.01$; Fig. 2e). As for the prognostic index (PI), patients with a score of 0 (median OS, 12.5 months) had a significantly better OS as compared to those with a score of 1 (median OS, 7.8 months) and 2 (median OS, 3.2 months), respectively (score of 1 HR, 2.01; 95%CI, 1.48–2.71; $P < 0.01$; score of 2 HR, 12.99; 95%CI, 5.80–29.13; $P < 0.01$; Fig. 2f). On multivariate analysis that included Eastern Cooperative Oncology Group performance status (ECOG-PS), carbohydrate antigen 19–9 (CA19-9), CAR, age, and the number of metastases, CAR was significantly associated with OS (adjusted HR 1.66; 95%CI 1.17–2.34; $P < 0.01$). Supplemental Fig. 1a–f presents the progression-free survival (PFS) of patients after dividing them into sets of two groups by six inflammatory markers in first-line chemotherapy. There were significant differences between the groups in all markers except for PLR. Supplemental Fig. 2a–f presents the data for the FFX and GnP subgroups of the 6 inflammatory markers. The Supplemental Table presents the baseline characteristics of the CAR < 0.54 group and CAR ≥ 0.54 group for both the first- and second-line treatments. There were several significant differences in the patient characteristics, such as for the performance status (PS) or laboratory data, and between the CAR < 0.54 and CAR ≥ 0.54 groups for both the first- and second-line treatments. However, there was no significant difference observed between the two groups for the first-line regimens: FFX or GnP. Cox regression analysis for the four continuous variables, CAR, NLR, PLR, and PNI, was performed to compare their significance. In first-line chemotherapy, the HR of CAR was 1.72 (95%CI 1.47–2.01; $P < 0.01$). Similarly, the HRs of NLR, PLR, and PNI were 1.03 (95%CI 0.998–1.06; $P = 0.07$), 1.00 (95%CI 0.999–1.001; $P = 0.29$), and 0.98 (95%CI 0.96–0.999; $P = 0.04$), respectively.

Inflammatory markers observed during second-line chemotherapy. In order to determine the most significant inflammatory marker that can be used to predict survival, we calculated the area under the curves (AUCs) for each of the markers to assess the prognosis performance for the first-line chemotherapy. CAR exhibited the highest value with regard to the 4- to 16-month OS (Fig. 3). When we calculated the Akaike's information criterions (AICs) for the 6 markers used for the sensitivity analysis, the AICs for CAR, NLR, PLR, PNI, GPS, and PI were 1828.355, 1859.623, 1861.325, 1858.183, 1846.128, and 1829.535, respectively. Thus, as it was the most significant inflammatory marker with regard to the OS for the second-line chemotherapy in each patient group, we focused our analysis on CAR. After undergoing first-line chemotherapy, there were 159 patients who received second-line chemotherapy (Fig. 1). Of these, 119 patients were allocated to the CAR < 0.54 group, while there were 40 allocated to the CAR ≥ 0.54 group (Table 1). The median OS for the entire CAR < 0.54




Figure 2. Kaplan–Meier curves for overall survival in first-line chemotherapy. (a) CAR < 0.54 group versus CAR ≥ 0.54 group, (b) NLR < 5 group versus NLR ≥ 5 group, (c) PNI ≥ 47 group versus PNI < 47 group, (d) PLR < 150 group versus PLR ≥ 150 group, (e) GPS score of 0 versus score of 1 versus score of 2, (f) PI score of 0 versus score of 1 versus score of 2. CAR C-reactive protein/albumin ratio, NLR neutrophil–lymphocyte ratio, PNI prognostic nutrition index, PLR platelet–lymphocyte ratio, GPS modified Glasgow prognostic score, PI prognostic index.




Figure 3. AUC of the time-dependent ROC curve for the prognostic performance evaluation of each inflammatory marker. AUC area under the curve, ROC receiver-operating characteristic, CAR C-reactive protein/albumin ratio, NLR neutrophil–lymphocyte ratio, PNI prognostic nutrition index, PLR platelet–lymphocyte ratio, GPS modified Glasgow prognostic score, PI prognostic index.

group was 5.6 months, while it was 3.4 months for the entire $CAR \geq 0.54$ group. There was a statistically significant difference between these two groups (HR 1.79; 95%CI 1.21–2.67; $P < 0.01$; Fig. 4a). The median OS of the $NLR < 5$ group was 5.5 months, while it was 3.5 months in the $NLR \geq 5$ group, which was statistically significant (HR for death, 1.73; 95%CI, 1.14–2.63; $P = 0.01$; Fig. 4b). The median OS was 6.3 months for the $PNI \geq 47$ group, while it was 4.9 months for the $PNI < 47$ group (HR 1.44; 95%CI 0.89–2.34; $P = 0.14$; Fig. 4c). The median OS was 5.3 months for the $PLR < 150$ group, while it was 4.9 months for the $PLR \geq 150$ group (HR 1.00; 95%CI 0.71–1.42; $P = 0.98$; Fig. 4d). In addition, patients with a GPS score of 0 (median OS, 6.3 months) had a significantly better OS as compared to those with a GPS score of 2 (median OS, 2.4 months; HR, 2.43; 95%CI, 1.53–3.87; $P < 0.01$). However, this was not better than that for the patients with a GPS score of 1 (median OS, 5.2 months; HR, 1.17; 95%CI, 0.79–1.73; $P = 0.44$; Fig. 4e). As for the PI, although patients with a score of 0 (median OS, 6.3 months) had a significantly better OS as compared to those with a score of 1 (median OS, 4.2 months; HR, 1.50; 95%CI, 1.03–2.16; $P = 0.03$), this was not better as compared to those with a score of 2 (median OS, 3.4 months; HR, 1.89; 95%CI, 0.82–4.34; $P = 0.14$; Fig. 4f). Supplemental Fig. 3a–f presents the PFS of patients after dividing them into sets of two groups by six inflammatory markers in second-line chemotherapy. There were no significant differences between the groups in all markers.

In the FFX cases, the median OS for the $CAR < 0.54$ group was 4.9 months, while it was 4.6 months in the $CAR \geq 0.54$ group (HR 2.17; 95%CI 0.56–8.44; $P = 0.27$; Supplemental Fig. 4a). There was a statistically significant difference observed in the GnP cases ($CAR < 0.54$, 6.7 months; $CAR \geq 0.54$, 5.1 months; HR 2.25; 95%CI 1.19–4.25; $P = 0.01$; Supplemental Fig. 4b). In other regimens, the median OS for the $CAR < 0.54$ group was 5.2 months, whereas it was 2.9 months for the $CAR \geq 0.54$ group. There was no significant difference between these two groups (HR 1.64; 95%CI 0.93–2.88; $P = 0.09$; Supplemental Fig. 4c). On multivariate analysis that included Eastern Cooperative Oncology Group performance status (ECOG-PS), carbohydrate antigen 19–9 (CA19–9), CAR, age, and the number of metastases, CAR was significantly associated with OS (adjusted HR 1.95; 95%CI 1.24–3.06; $P < 0.01$). Table 3 shows the distribution of the CAR-high and CAR-low between Cohorts 1 and 2. Cox regression analysis for the four continuous variables, CAR, NLR, PLR, and PNI, was performed to compare their significance. In second-line chemotherapy, the HR of CAR was 1.37 (95%CI 1.17–1.61; $P < 0.01$). Similarly, the HRs of NLR, PLR, and PNI were 1.02 (95%CI 0.99–1.06; $P = 0.16$), 1.00 (95%CI 0.999–1.001; $P = 0.54$), and 0.94 (95%CI 0.91–0.98; $P < 0.01$), respectively.

Discussion

We investigated the adequacy of the prognosis prediction by measuring each of the six inflammatory markers at the start of both the first- and second-line chemotherapy treatments for Japanese pancreatic cancer patients who were undergoing palliative chemotherapy. Recently, NLR, CAR, and PNI have been evaluated for use as prognostic markers in pancreatic cancer^{20–24}. These markers were reported to be useful for predicting survival among various diseases or therapeutic stages. For example, GPS was shown to be an independent marker of poor prognosis in hepatocellular carcinoma¹⁶, CAR was associated with the OS in hepatocellular carcinoma²⁵, and NLR was an independent indicator of poor prognosis in patients with pancreatic cancer at the time of diagnosis^{17,21}. Although previous reports have suggested that inflammatory markers might be useful as a predictor of the prognosis at a limited stage, our outcomes suggest that CAR could be the most significant biomarker, as it appears to be able to predict the survival of unresectable pancreatic cancer patients at the start of both the first- and second-line chemotherapy treatments. This study was carried out as a post-hoc analysis of the NAPO-LEON study¹⁹, with the results showing that OS in the FFX and GnP groups was about 11 months. Our current study appears to be a proper analysis of valid clinical cases that meet the criteria for chemotherapy, with the data generally corresponding with the results of previous pivotal clinical trials^{4,5} that reported a median follow-up duration of 10.7 months.




Figure 4. Kaplan–Meier curves for overall survival in the second-line chemotherapy patients. (a) CAR < 0.54 group versus CAR ≥ 0.54 group, (b) NLR < 5 group versus NLR ≥ 5 group, (c) PNI ≥ 47 group versus PNI < 47 group, (d) PLR < 150 group versus PLR ≥ 150 group, (e) GPS score of 0 versus score of 1 versus score of 2, (f) PI score of 0 versus score of 1 versus score of 2. CAR C-reactive protein/albumin ratio, NLR neutrophil–lymphocyte ratio, PNI prognostic nutrition index, PLR platelet–lymphocyte ratio, GPS modified Glasgow prognostic score, PI prognostic index.

		Cohort 2			
		CAR-high	CAR-low	N/A	Total
Cohort 1	CAR-high	19	18	25	62
	CAR-low	21	101	71	193
	Total	40	119	96	255

Table 3. Distribution of CAR-high and CAR-low between the Cohorts 1 and 2. CAR CRP-albumin ratio, N/A not applicable.

We initially analyzed the prognosis of unresectable pancreatic cancer patients who underwent the standard first-line chemotherapy of FFX or GnP, by examining six inflammatory markers. While there was significant stratification of the OS observed for every inflammatory marker in all of the patients administered FFX, this was only seen for CAR in patients with GnP, when the analysis was carried out in more than 10 cases in each study arm. To definitively evaluate this, further analyses for the other markers in GnP cases will need to be undertaken, as our data showed there was a tendency of stratification in the OS at each of the cut-offs. The hazard ratio of CAR was the highest for the stratified analysis of the two arms. Furthermore, the AUC of the time-dependent ROC curve for the prognostic performance evaluation done during the first-line treatment showed that the best predictive value was for CAR. Thus, we speculated that CAR might be the best marker for predicting the survival at the initiation of first-line chemotherapy. As the median OS for the first-line chemotherapy in patients with unresectable pancreatic cancer has been reported to be 11.1 months⁵, and as the median OS for the CAR < 0.54 group was 12.1 months in our current study, this suggests that CAR might be the best tool for predicting the OS prior to the induction of chemotherapy. However, since the median OS for the CAR ≥ 0.54 group was 7.2 months, which was longer than the 6.8 months for patients being treated with gemcitabine⁴, the indication for chemotherapy should not be excluded for the CAR < 0.54 group. Although we also demonstrated there was a statistical significance for the PI, there were only a small number of patients with a score of 2 that were evaluated, thus making it hard to generalize the overall results. However, it is possible that GPS might also be useful in first-line cases.

In all cases that received second-line chemotherapy, OS was significantly longer in the CAR < 0.54 group than in CAR ≥ 0.54 group (median OS; 5.6 vs. 3.6 months). They were within the median OS of second- or later-line chemotherapy (3 to 9 months^{6–9}), although the cohort 2 group included 50% of the gemcitabine-refractory patients. As both monotherapy and combination-therapy were included in the second-line regimens used in our study, this suggests that CAR might be a useful prognostication tool reflecting these initial cases. However, we cannot definitively state that this second-line chemotherapy was not effective for the CAR ≥ 0.54 group, as the OS of the fluorouracil group was 3.3 months⁷. There was no statistical significance found for the PNI, PLR, GPS, and PI. Significance was also shown for the NLR with the HR equal to that found for CAR. However, we considered CAR to be superior to NLR based on the HR of CAR, along with the fact that the AIC and AUC were higher for the first-line treatments. In addition, comparing the prognostic significance of CAR with that of other inflammatory parameters using their median values is important. The cut-off values of PLR and PNI in this study were very close to the median values without prognostic significance, so additional analyses were performed for CAR and NLR. Only CAR showed prognostic significance in both first and second lines using median values (Supplemental Fig. 5a–d). The present study included 255 patients, more than the previous study²⁰, so the CAR cut-off of 0.54 could have enriched more aggressive disease in the CAR high group in first-line chemotherapy. However, the present study was retrospective, and we are now confirming the repeatability of the CAR cut-off of 0.54 in a prospective study with a different cohort.

CAR is calculated based on the serum concentrations of CRP and albumin. The inflammatory mediator, interleukin-6 (IL-6), is a remarkable inflammatory cytokine that is secreted by the immune cells or tumor cells that regulate the levels of CRP²⁶, in addition to mediating the chemoresistance²⁷. Also, it has been reported that IL-6 and CRP exhibit a significant correlation with their elevation related to poor survival^{20,28–30}. Moreover, the IL-6 level reflects the state of the tumor³¹. Thus, a higher CRP is considered to be a prognostic factor, with previous results showing associations with various types of cancers in patients³². In gastroenterological cancers, it has been reported that there is a strong relationship between inflammation and low albumin levels³³. Inflammatory cytokines suppress albumin synthesis at the hepatocytes^{34,35}, with changes in the serum albumin concentration influencing the pharmacokinetics and hematologic toxicity in chemotherapy³⁶. Low albumin causes a decrease in the binding-rate of anti-cancer drugs³⁷, and increases in adverse events³⁸. Therefore, as low albumin levels are known to weaken the effect of the chemotherapy, pretreatment albumin levels can be used to predict OS^{39–41}. The reasons why CAR had greater prognostic power than other inflammatory markers were further considered. GPS and PI had the disadvantage of being categorical variables that failed to accurately reflect each patient's disease condition. PLR and PNI were proven to be useful markers mainly for perioperative pancreatic cancer patients^{23,24,46}, different from our inclusion criteria. There might be a large difference between previous studies and the present study because the present study excluded patients with locally advanced pancreatic cancer^{20,21}. Therefore, CAR could show better prognostic significance than NLR both in first and second lines, on both Cox regression analysis and stratified analysis using their median values. Taken together, this suggests that CAR might be regarded as a prognostic marker. Doctors and patients could better prepare for future clinical courses if it is known that a patient's prognosis would be predicted to be poor. In our present study, although it appeared that CAR might be the most significant inflammatory marker that can be used for unresectable pancreatic cancer

cases, we will need to prospectively collect and analyze further data, as the other five markers also showed effectiveness in predicting the OS.

There were some limitations to the present study. First, as this study was a nonrandomized and retrospective study, our results could have been affected by selection bias. Moreover, we also need to consider differences in the patient characteristics that are present between the CAR-high and the CAR-low groups. Second, as our study included cases using FFX or GnP as first-line chemotherapy, we did not analyze the use of other regimens as first-line treatments. To overcome these limitations, we are now planning to undertake other prospective and retrospective studies with different cohorts consisting of all regimens in order to confirm the repeatability. Third, the ethnicity and location of the enrolled patients were limited given the present study's focus on Japanese patients. Despite this, we were able to find common points between the current and previously reported studies^{20,22}. Thus, these results suggest that CAR might be a universal marker. In addition, the present study only included a small number of patients who were diagnosed with malignancy based on imaging studies rather than by histological or cytological diagnoses. Moreover, there tended to be some patients evaluated during routine clinical practices who had no other choice except to undergo systemic chemotherapy in the absence of any histological evidence due to a variety of reasons, such as for example, patients who were diagnosed based on emergency or anatomically difficult positions. Thus, in order to build stronger evidence to support the findings of the present study, further studies are warranted.

In conclusion, CAR might be a significant and easy-to-use biomarker that can be utilized for accurate prediction of the prognosis in Japanese patients with unresectable pancreatic cancer who are undergoing first- and second-line chemotherapy. This information could further help clinicians to select appropriate therapeutic strategies for the individualized management of these patients.

Methods

Study design. This analysis was performed as a post-hoc analysis of the multicenter retrospective study of GnP or FFX in patients with unresectable pancreatic cancer (NAPOLEON study) that was conducted by specialists from 14 centers specializing in medical oncology and gastroenterology in Japan. The NAPOLEON study was approved by the Institutional Review Boards of each participating institution. We retrospectively reviewed the medical records of consecutive patients with unresectable and recurrent pancreatic cancer who were started on FFX or GnP as a first-line chemotherapy. The main results of the NAPOLEON study have been previously reported¹⁹.

From December 2013 to March 2017, 318 patients with advanced or recurrent pancreatic cancer received GnP or FFX as first-line chemotherapy. After excluding 63 locally advanced cases, 255 patients who received first-line chemotherapy were analyzed using the data from before the start of the first-line treatment. Subsequently, 159 patients who underwent second-line chemotherapy were then analyzed using the data obtained from just before the start of the second-line treatment (Fig. 1).

Treatment methods. GnP was administered as follows: nab-paclitaxel (125 mg/m²), 30-min intravenous infusion; 30-min gemcitabine (1000 mg/m²), intravenous infusion on days 1, 8, and 15 every 4 weeks⁴. The FFX group was comprised of patients who received both the original and modified regimens. Original-FFX was sequentially administered as follows: oxaliplatin (85 mg/m²), 2-h intravenous infusion; l-leucovorin (200 mg/m²), 2-h intravenous infusion; intravenous infusion of irinotecan (150–180 mg/m²), 30 min later and over a 90-min period; fluorouracil (400 mg/m²), an intravenous bolus; and continuous intravenous fluorouracil infusion (2400 mg/m²) for 46 h every 2 weeks⁵. Modified-FFX was sequentially administered as follows: oxaliplatin (85 mg/m²), 2-h intravenous infusion; l-leucovorin (200 mg/m²), 2-h intravenous infusion; irinotecan (150 mg/m²), intravenous infusion 30 min later over a 90-min period; and continuous intravenous fluorouracil infusion (2400 mg/m²) for 46 h every 2 weeks⁴².

Definition of inflammatory markers. CAR was calculated as follows: serum CRP level (mg/dL) divided by the serum albumin level (g/dL). Similarly, NLR and PLR were calculated as follows: neutrophil count (/μL) divided by the lymphocyte count (/μL), platelet count (/μL) divided by the lymphocyte count (/μL), respectively. We calculated the PNI using the following formula: $10 \times \text{serum albumin level (g/dL)} + 0.005 \times \text{lymphocyte count (/μL)}$. The score of the GPS was defined as follows: serum CRP level ≤ 1.0 (mg/dL) and serum albumin level ≥ 3.5 (g/dL), score of 0; CRP > 1.0 (mg/dL) or albumin < 3.5 (g/dL), score of 1; CRP > 1.0 (mg/dL) and albumin < 3.5 (g/dL), score of 2. In addition, the score of the PI was defined as follows: serum CRP level ≤ 1.0 (mg/dL) and white blood cell count (WBC) ≤ 11,000/μL, score of 0; CRP > 1.0 (mg/dL) and WBC ≤ 11,000 (/μL), score of 1; CRP ≤ 1.0 (mg/dL) and WBC > 11,000 (/μL), score of 1; CRP > 1.0 (mg/dL) and WBC > 11,000 (/μL), score of 2.

Evaluations and statistical analysis. Patient characteristics evaluated at the start of first- and second-line chemotherapy included age, sex, ECOG performance status, past history, primary tumor site, disease status, metastatic site, treatment regimen at the first-line chemotherapy, lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), CA19-9 and inflammatory factors. These were all analyzed in order to investigate the correlation with the prognosis by Cox regression model. We used the multiple imputation method⁴³ to impute missing data for white blood cell count, neutrophil count, lymphocyte count, platelet count, albumin concentration, and C-reactive protein concentration. The cut-off values for CAR, NLR, PLR, and PNI were adopted as 0.54, 5, 150, and 47, respectively, based on previous studies^{20,44–47}. Subsequently, patients were then divided into two groups (low or high) according to each of the inflammatory markers. The compatibility of inflammatory markers was examined through the use of the AUC of the time-dependent ROC curve⁴⁸. These results were then used to evaluate the prognostic performance for each of the inflammatory markers. We also used the AIC for the sensi-

tivity analysis. This was a mathematical method that is used for evaluating how well a model fits the data it was generated from, with the best-fit model defined as that with the lowest value for the AIC⁴⁹.

OS was calculated from the date of administration of the first-line or second-line chemotherapy to the date of death from any cause or was censored at the final follow-up examination. PFS was calculated from the date of first-line or second-line chemotherapy administration to the date of progression or death from any cause, whichever occurred first or was censored at the final follow-up examination.

Survival was estimated using the Kaplan–Meier method, with comparisons of the probability of survival performed using the log-rank test and the Cox proportional hazards model. HRs are expressed with 95% CIs. Factors showing differences with *P* values of < 0.05 were considered statistically significant. Prognostic factors judged to be clinically meaningful and those with *P* values of < 0.05 were selected. Data were collected by clinicians with expertise in clinical research under the supervision of the statistician and then centrally managed. This study was conducted with the approval of the Institutional Review Board of each participating institution, and in accordance with the provisions of the Declaration of Helsinki. Statistical analyses were performed using R version 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria).

Ethics approval and consent to participate. This study was conducted in accordance with the ethical guideline of the Declaration of Helsinki and was centrally approved by the Institutional review board of Saga Medical Center Koseikan (study ID 17-09-01-02), and also approved by the Institutional Review Boards or Ethics Committee of following institutions: Imari Arita Kyoritsu Hospital, Japanese Red Cross Kumamoto Hospital, Kagoshima City Hospital, Oita University Hospital, Kagoshima University Hospital, Kurume University Hospital, Japan Community Healthcare Organization Kyushu Hospital, Saiseikai Sendai Hospital, Nagasaki University Hospital, Hamanomachi Hospital, Sasebo Kyosai Hospital, Karatsu Red Cross Hospital and Fukuoka Wajiro Hospital prior to the study. Because this study was a retrospective observational study carried out in Japan, informed consent was obtained using the opt-in/opt-out approach according to each participating institution's policy.

Data availability

All data generated or analyzed in this study are stored in a secured research database. Although they are not publicly available, they are available through the corresponding author upon reasonable request.

Code availability

We used R ver. 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria) for statistical analyses.

Received: 19 February 2023; Accepted: 10 May 2023

Published online: 31 May 2023

References

1. The editorial board of the cancer statistics in Japan. Cancer Statistics in Japan-2019. Foundation for Promotion of Cancer Research (FPCR) 2020.
2. Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* **68**(6), 394–424 (2018).
3. Kamisawa, T. *et al.* *Lancet* **388**, 73–85 (2016).
4. Von Hoff, D. D. *et al.* Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N. Engl. J. Med.* **369**, 1691–1703 (2013).
5. Conroy, T. *et al.* FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N. Engl. J. Med.* **364**, 1817–1825 (2011).
6. Wang-Gillam, A. *et al.* Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomized, open-label, phase 3 trial. *Lancet* **387**, 545–557 (2016).
7. Oettle, H. *et al.* Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. *J. Clin. Oncol.* **32**, 2423–2429 (2014).
8. Gill, S. *et al.* PANCREOX: A randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *J. Clin. Oncol.* **34**, 3914–3920 (2016).
9. Ioka, T. *et al.* TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase 3 study (GRAPE trial). *Eur. J. Cancer* **106**, 78–88 (2019).
10. Golan, T. *et al.* Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N. Engl. J. Med.* **381**(4), 317–327 (2019).
11. Carrato, A. *et al.* A systematic review of the burden of pancreatic cancer in Europe: Real-world impact on survival, quality of life and costs. *J. Gastrointest. Cancer* **46**, 201–211 (2015).
12. Egawa, S. *et al.* Japan pancreatic cancer registry; 30th year anniversary: Japan Pancreas Society. *Pancreas* **41**, 985–992 (2012).
13. Hang, J. *et al.* Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. *Cancer Med* **7**(7), 2974–2984 (2018).
14. Goldstein, D. *et al.* Nomogram for estimating overall survival in patients with metastatic pancreatic cancer. *Pancreas* **49**(6), 744–750 (2020).
15. Coussens, L. M. *et al.* Inflammation and cancer. *Nature* **6917**, 860–867 (2002).
16. Kinoshita, A. *et al.* Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. *Br. J. Cancer.* **6**, 988–993 (2012).
17. Inoue, D. *et al.* Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: A retrospective study in a single institute in Japan. *Jpn. J. Clin. Oncol.* **1**, 61–66 (2015).
18. Ide, Y. *et al.* Conversion surgery for unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. *Anticancer Res.* **43**, 1817–1826 (2023).
19. Otsuka, T. *et al.* A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: Results from the NAPOLEON study. *Int. J. Clin. Oncol.* **26**(5), 941–950 (2021).
20. Wu, M. *et al.* The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. *Tumour. Biol.* **37**, 12525–12533 (2016).
21. Iwai, N. *et al.* Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. *Sci. Rep.* **10**, 18758 (2020).

22. Liu, Z. *et al.* Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. *Ann. Surg. Oncol.* **24**(2), 561–568 (2017).
23. Ikeguchi, M. *et al.* Clinical importance of preoperative and postoperative prognostic nutritional index in patients with pancreatic ductal adenocarcinoma. *Ann. Hepatobiliary. Pancreat. Surg.* **23**, 372–376 (2019).
24. Kanda, M. *et al.* Nutritional predictors of postoperative outcome in pancreatic cancer. *Br. J. Surg.* **98**, 268–274 (2011).
25. Kinoshita, A. *et al.* The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. *Ann. Surg. Oncol.* **3**, 803–810 (2015).
26. McKeown, D. J. *et al.* The relationship between circulating concentrations of C reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. *Br. J. Cancer.* **91**, 1993–1995 (2004).
27. Abdul Rahim, S. N. *et al.* The role of interleukin-6 in malignant mesothelioma. *Transl. Lung Cancer Res.* **4**, 55–66 (2015).
28. Szkandera, J. *et al.* Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. *Br. J. Cancer.* **110**, 183–188 (2014).
29. Pine, J. K. *et al.* Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. *Eur. J. Surg. Oncol.* **35**, 605–610 (2009).
30. Kishi, T. *et al.* Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. *Pancreatol.* **15**, 694–700 (2015).
31. Nakano, T. *et al.* Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. *Br. J. Cancer* **77**, 907–912 (1998).
32. Allin, K. H. *et al.* Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. *Crit. Rev. Clin. Lab. Sci.* **48**(4), 155–170 (2011).
33. Nazha, B. *et al.* Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate?. *World J. Gastrointest. Surg.* **7**, 370–377 (2015).
34. Fearon, K. C. *et al.* Cancer cachexia: Mediators, signaling, and metabolic pathways. *Cell Metab* **16**, 153–166 (2012).
35. Petruzzelli, M. *et al.* Mechanisms of metabolic dysfunction in cancer-associated cachexia. *Genes Dev.* **30**, 489–501 (2016).
36. Joel, S. P. *et al.* Predicting etoposide toxicity: Relationship to organ function and protein binding. *J. Clin. Oncol.* **14**(1), 257–267 (1996).
37. Minami, H. *et al.* Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. *Cancer Sci.* **97**, 235–241 (2006).
38. Alexandre, J. *et al.* Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. *Ann. Oncol.* **14**, 36–41 (2003).
39. Boonpipattanapong, T. *et al.* Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. *J. Clin. Gastroenterol.* **40**, 592–595 (2006).
40. Siddiqui, A. *et al.* Predictors of early mortality in veteran patients with pancreatic cancer. *Am. J. Surg.* **194**, 362–366 (2007).
41. Onate-Ocana, L. F. *et al.* Serum albumin as a significant prognostic factor for patients with gastric carcinoma. *Ann. Surg. Oncol.* **14**, 381–389 (2007).
42. Ozaka, M. *et al.* A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. *Cancer Chemother. Pharmacol.* **81**(6), 1017–1023 (2018).
43. Morris, T. P. *et al.* Tuning multiple imputation by predictive mean matching and local residual draws. *BMC Med. Res. Methodol.* **14**, 75 (2014).
44. An, X. *et al.* Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. *Biomarkers* **15**, 516–522 (2010).
45. Goldstein, D. *et al.* nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. *J. Natl. Cancer Inst.* **31**, 107 (2015).
46. Richard, A. S. *et al.* Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. *Am. J. Surg.* **197**(4), 466–72 (2009).
47. Geng, Y. *et al.* Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. *Eur. J. Surg. Oncol.* **41**(11), 1508–1514 (2015).
48. Heagerty, P. J. *et al.* *Biometrics* **56**, 337–344 (2000).
49. Akaike, H. A new look at the statistical model identification. *IEEE Trans. Automat. Control* **19**(6), 716–723 (1974).

Acknowledgements

We thank all of the patients and their families, and all of the investigators at the 14 institutions that participated in the NAPOLEON study. We would also like to thank the Fukuoka Medical Oncology Group – Kyushu Yamaguchi Total Oncology Group (FMOG-KYTOG) and the Saga Study Group of Liver Disease (SASLD) for their cooperation. We are indebted to Dr. Yasunori Kawaguchi of the Saga Medical Centre Koseikan, and Dr. Masato Uenomachi of the Hamanomachi Hospital for their assistance in the data collection or discussion. We also thank Forte Science Communications for providing medical writing support.

Author contributions

T.S., T.O., N.U., T.M., and K.M. created the study concept. T.S., T.O., M.S., A.M., M.F., N.U., T.M., and K.M. designed the study. T.S., A.M., T.O., Y.S., F.K., Y.U., J.N., S.O., A.K., S.A., M.F., H.T., T.H., T.S., K.N., Y.I., N.U., T.M., and K.M. acquired the clinical data. T.S., M.S., T.O., and K.M. were involved in the quality control of the data and algorithms. T.S., T.O., M.S., A.M., T.M., K.M., and E.B. were involved in the data analysis and interpretation. T.S., T.O., M.S., K.M., and E.B. performed statistical analysis. T.S. prepared the manuscript, and it was edited by T.S., T.O., M.S., T.M., K.M., and E.B. The manuscript was critically reviewed by all authors, and they approved the final version. The requirement for consent for publication was waived because of the retrospective design of this study.

Funding

This study did not receive any funding.

Competing interests

M.S. received a personal fee from Sysmex Corporation; S.A. received personal fees from Taiho Pharmaceutical, Novartis Pharma, Chugai, Bristol-Myers Squibb, Daiichi-Sankyo, and AstraZeneca; A.M. received personal fees from Eli Lilly, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb and Daiichi-Sankyo. The remaining authors have no competing interests or financial disclosures to declare.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-34962-7>.

Correspondence and requests for materials should be addressed to K.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Supplemental Figure legends

Supplemental Figure 1.

Kaplan-Meier curves for progression-free survival in the first-line chemotherapy patients. (a) $CAR < 0.54$ group versus $CAR \geq 0.54$ group, (b) $NLR < 5$ group versus $NLR \geq 5$ group, (c) $PNI \geq 47$ group versus $PNI < 47$ group, (d) $PLR < 150$ group versus $PLR \geq 150$ group, (e) GPS score of 0 versus score of 1 versus score of 2, (f) PI score of 0 versus score of 1 versus score of 2.

CAR C-reactive protein/albumin ratio, *NLR* neutrophil–lymphocyte ratio, *PNI* prognostic nutrition index, *PLR* platelet–lymphocyte ratio, *GPS* modified Glasgow prognostic score, *PI* prognostic index

Supplemental Figure 2.

Kaplan-Meier curves for overall survival for the FFX or GnP cases in first-line chemotherapy patients. $CAR < 0.54$ group versus $CAR \geq 0.54$ group in the FFX (a) and GnP (b) cases, $NLR < 5$ group versus $NLR \geq 5$ group in the FFX (c) and GnP (d) cases, $PNI \geq 47$ group versus $PNI < 47$ group in the FFX (e) and GnP (f) cases, $PLR < 150$ group versus $PLR \geq 150$ group in the FFX (g) and GnP (h) cases, GPS score of 0 versus score of 1 versus score of 2 in FFX (i) and GnP (j) cases, PI score of 0 versus score of 1 versus score of 2 in the FFX (k) and GnP (l) cases.

FFX FOLFIRINOX, *GnP* gemcitabine plus nab-paclitaxel, *CAR* C-reactive protein/albumin ratio, *NLR* neutrophil–lymphocyte ratio, *PNI* prognostic nutrition index, *PLR* platelet–lymphocyte ratio, *GPS* modified Glasgow prognostic score, *PI* prognostic index

Supplemental Figure 3.

Kaplan-Meier curves for progression-free survival in the second-line chemotherapy patients. (a) $CAR < 0.54$ group versus $CAR \geq 0.54$ group, (b) $NLR < 5$ group versus $NLR \geq 5$ group, (c) $PNI \geq 47$ group versus $PNI < 47$ group, (d) $PLR < 150$ group versus $PLR \geq 150$ group, (e) GPS score of 0 versus score

of 1 versus score of 2, (f) PI score of 0 versus score of 1 versus score of 2.

CAR C-reactive protein/albumin ratio, *NLR* neutrophil–lymphocyte ratio, *PNI* prognostic nutrition index, *PLR* platelet–lymphocyte ratio, *GPS* modified Glasgow prognostic score, *PI* prognostic index

Supplemental Figure 4.


Kaplan-Meier curves for overall survival for the FFX or GnP cases in second-line chemotherapy patients. $CAR < 0.54$ group versus $CAR \geq 0.54$ group in the FFX (a), GnP (b) and other (c) cases.

FFX FOLFIRINOX, *GnP* gemcitabine plus nab-paclitaxel, *CAR* C-reactive protein/albumin ratio

Supplemental Figure 5.


Kaplan-Meier curves for overall survival in the first- and second-line chemotherapy patients. (a) $CAR < 0.084$ group versus $CAR \geq 0.084$ group in first-line, (b) $NLR < 3.02$ group versus $NLR \geq 3.02$ group in first-line, (c) $CAR < 0.157$ group versus $CAR \geq 0.157$ group in second-line, (d) $NLR < 2.68$ group versus $NLR \geq 2.68$ group in second-line.

CAR C-reactive protein/albumin ratio, *NLR* neutrophil–lymphocyte ratio



No. at risk


193	45	8	3	0	0
62	9	1	0	0	0



No. at risk


209	48	9	3	0	0
46	6	0	0	0	0

Probability




No. at risk

—	98	23	6	2	0	0
—	157	31	3	1	0	0




No. at risk

127	32	4	0	0	0
128	22	5	3	0	0



No. at risk


146	38	7	3	0	0
62	8	1	0	0	0
47	8	1	0	0	0



No. at risk


165	41	7	3	0	0
82	13	2	0	0	0
8	0	0	0	0	0

SF 2a



No. at risk

76	51	12	5	2	0
26	8	1	0	0	0




No. at risk

117	69	16	3	0	0
36	13	6	0	0	0


+ NLR<5: median, 12.1 months
 + NLR≥5: median, 7.2 months

HR, 2.94
 95%CI, 1.69-5.09
 p<0.01




No. at risk

■	83	55	12	5	2	0
■	19	4	1	0	0	0




No. at risk

126	70	18	3	0	0
27	12	4	0	0	0




No. at risk

45	27	6	5	2	0
57	32	7	0	0	0



No. at risk


■	53	26	7	0	0	0
■	100	56	15	3	0	0



No. at risk


■	54	36	8	3	1	0
■	48	23	5	2	1	0

Probability




No. at risk

73	43	14	2	0	0
80	39	8	1	0	0




No. at risk

64	47	11	5	2	0
21	7	0	0	0	0
17	5	2	0	0	0




No. at risk

82	49	12	2	0	0
41	22	5	1	0	0
30	11	5	0	0	0




No. at risk

67	48	11	5	2	0
31	11	2	0	0	0
4	0	0	0	0	0




No. at risk

98	62	16	3	0	0
51	20	6	0	0	0
4	0	0	0	0	0




No. at risk

119	7	1	0	0	0
40	2	0	0	0	0




No. at risk

125	7	1	0	0	0
34	2	0	0	0	0




No. at risk

26	3	0	0	0	0
133	6	1	0	0	0




No. at risk

70	3	1	0	0	0
89	6	0	0	0	0



No. at risk


80	5	1	0	0	0
48	3	0	0	0	0
31	1	0	0	0	0



No. at risk


100	7	1	0	0	0
49	1	0	0	0	0
10	1	0	0	0	0

Probability




No. at risk

11	4	2	0	0	0
3	1	0	0	0	0



No. at risk


48	13	1	0	0	0
14	0	0	0	0	0



No. at risk

60	9	2	2	0	0
23	2	0	0	0	0


Probability



No. at risk


127	89	23	7	2	0
128	52	12	1	0	0

Probability




No. at risk

127	82	20	6	1	0
128	59	15	2	1	0



No. at risk

79	19	4	1	0	0
80	10	1	1	0	0



No. at risk

79	16	4	2	0	0
80	13	1	0	0	0

Supplemental Table. Baseline characteristics of the CAR < 0.54 group and CAR ≥ 0.54 group

Characteristics		Cohort 1			Cohort 2		
		CAR < 0.540	CAR ≥ 0.540	P	CAR < 0.540	CAR ≥ 0.540	P
		n=193 (%)	n=62 (%)		n=119 (%)	n=40 (%)	
Age, years	median (range)	66 (29–86)	63 (35–77)	< 0.01	65 (29–87)	62 (36–80)	0.24
	≥ 65 y.o.	110 (57)	20 (32)	< 0.01	62 (52)	16 (40)	0.19
Sex, n (%)	male	119 (62)	39 (63)	0.86	119 (62)	39 (63)	0.49
ECOG PS, n (%)	0	130 (67)	31 (50)	< 0.01	54 (45)	9 (23)	0.047
	1	56 (29)	22 (35)		52 (44)	22 (55)	
	≥ 2	7 (4)	9 (15)		13 (11)	8 (20)	
	unknown	0 (0)	0 (0)		0 (0)	1 (3)	
Malignant history, n (%)	yes	28 (15)	6 (10)	0.52	16 (13)	3 (8)	0.14
Malignant family history, n (%)	yes	59 (31)	16 (26)	0.77	41 (34)	7 (18)	0.04
Previous tumor resection, n (%)	yes	40 (21)	4 (6)	0.01	18 (15)	2 (5)	0.10
Previous biliary drainage, n (%)	yes	56 (29)	9 (15)	0.02	29 (24)	10 (25)	0.94
Pancreatic tumor location, n (%)	head	101 (52)	22 (35)	0.02	57 (48)	18 (45)	0.75
	body/tail	92 (48)	40 (65)		62 (52)	22 (55)	
Histology, n (%)	adenocarcinoma	157 (81)	55 (89)	0.35	104 (87)	34 (85)	0.91
	others	9 (5)	1 (2)		2 (2)	1 (3)	
	unknown	27 (14)	6 (10)		13 (11)	5 (13)	
Site of metastatic disease, n (%)	liver	105 (54)	49 (79)	< 0.01	73 (61)	27 (68)	0.49
	peritoneum	48 (25)	14 (23)	0.72	31 (26)	6 (15)	0.15
	lung	33 (17)	6 (10)	0.16	17 (14)	5 (13)	0.78
Number of metastatic sites, n (%)	≥ 2	66 (34)	31 (50)	0.03	46 (39)	13 (33)	0.49
Ascites, n (%)	yes	36 (19)	20 (32)	0.02	23 (19)	6 (15)	0.54
First-line chemotherapy, n (%)	FFX	76 (39)	26 (42)	0.72	60 (50)	20 (50)	0.96
	GnP	117 (61)	36 (58)		59 (50)	20 (50)	
White blood cell count, /μL	median (range)	5590 (2400–11900)	8400 (4350–23650)	< 0.01	4100 (1620–14200)	7180 (1910–21910)	<0.01
Neutrophil count, /μL	median (range)	3620 (770–8680)	5750 (2240–20810)	< 0.01	2500 (610–11720)	5260 (1230–21250)	<0.01
Lymphocyte count, /μL	median (range)	1400 (440–3710)	1170 (230–8640)	0.02	1080 (260–2630)	1100 (190–3030)	0.95
Platelet count, ×10 ⁴ /μL	median (range)	19.9 (6.7–46.5)	23.3 (11.6–56.1)	< 0.01	17.6 (6.2–50.8)	20.5 (2.4–79.8)	0.07
Albumin concentration, g/dL	median (range)	4.0 (2.5–4.8)	3.34 (2.2–4.5)	< 0.01	3.7 (2.2–4.6)	3.3 (1.5–4.1)	< 0.01
CRP, mg/dL	median (range)	0.17 (0.01–2.12)	4.28 (1.73–17.0)	< 0.01	0.27 (0.01–2.00)	3.67 (2.00–16.33)	< 0.01
LDH, U/L	median (range)	174 (74–808)	203 (108–1320)	< 0.01	206 (84–713)	225 (112–447)	0.07
CEA, ng/mL	median (range)	4.7 (0.4–626.6)	13.9 (0.6–369.8)	< 0.01	7.2 (1.3–391.6)	10.8 (1.0–1379.3)	0.23
CA19-9, U/mL	median (range)	659 (1–1242609)	1821 (2–6554100)	0.12	808 (1–115905)	4111 (2–7200000)	0.02
NLR	median (range)	2.68 (0.28–8.37)	4.52 (1.25–36.88)	< 0.01	2.16 (0.37–30.00)	4.70 (1.32–49.42)	< 0.01
	≥ 5.00, n (%)	17 (9)	29 (47)	< 0.01	15 (13)	19 (48)	< 0.01
PLR	median (range)	137.3 (44.4–906.6)	209.5 (16.1–1344.8)	< 0.01	160.8 (46.6–1270.0)	178.4 (35.8–1043.1)	0.23
	≥ 150.0, n (%)	85 (44)	43 (69)	< 0.01	64 (54)	25 (63)	0.34
PNI	median (range)	46 (29–60)	39 (25–66)	< 0.01	43 (24–54)	39 (19–51)	< 0.01
	< 47, n (%)	104 (54)	53 (85)	< 0.01	95 (80)	38 (95)	0.03

CAR	median (range)	0.044 (0.002–0.523)	1.222 (0.546–7.182)	< 0.01	0.074 (0.003–0.513)	1.175 (0.562–6.387)	< 0.01
	≥ 0.540, n (%)	0 (0)	62 (100)	< 0.01	0 (0)	40 (100)	< 0.01
GPS, n (%)	0	146 (76)	0 (0)	< 0.01	80 (67)	0 (0)	< 0.01
	1	36 (19)	26 (42)		35 (29)	13 (33)	
	2	11 (6)	36 (58)		4 (3)	27 (68)	
PI, n (%)	0	165 (85)	0 (0)	< 0.01	100 (84)	0 (0)	< 0.01
	1	28 (15)	54 (87)		18 (15)	31 (78)	
	2	0 (0)	8 (13)		1 (1)	9 (23)	

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FFX, FOLFIRINOX; GnP, gemcitabine plus nab-paclitaxel; CRP, C-reactive protein; LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-lymphocyte ratio; PNI, prognostic nutrition index; CAR, CRP-albumin ratio; GPS, Glasgow prognostic score; PI, prognostic index.

